HBV Overview of the Last 3 Years For Drug Development: Phase 2 Trials

​

Presenter:

Ira M. Jacobson, MD

Is There a Real Difference between ETV and TDF/TAF in relapse and HCC?

​

Presenter:

W. Ray Kim, MD

Emerging Therapies in the Next 3 Years (Pre-clinical Phase 1)

​

Presenter:

Jorg Petersen, MD

Does the New Data on HBV DNA Integration and HBsAg Production Effect the Design and Definition of Treatment Endpoints of Phase II and Phase III Studies?

​

Presenter:

Ju-Tao Guo, MD

What Are the Most Promising Immunomodulatory Therapies for

HBV Infection?

​

Presenter:

Adam J. Gehring, PhD

How Do We Fit FNA and Liver Biopsy into HBV Drug Development and Design? Should All Studies Have FNA Subset and Examine Intrahepatic Immune Activity? CccDNA? Integrants?

​

Presenter:

Adam J. Gehring, PhD

Emerging Concepts and Data CPAMS Third and Fourth Generation

​

Presenter:

Man-Fung Yuen, MBBS, MD, PhD, DSc